https://www.selleckchem.com/pr....oducts/Cytarabine(Cy
e impact of different gene mutations on the outcome. Under two different measures, the variables were all KRAS mutations. It is suggested that the mutation of the KRAS gene is an independent predictor of the long-term benefit of immunotherapy. CONCLUSIONS The mutation of KRAS gene in tumor tissues is an independent predictor of the long-term benefit of immunotherapy, and the predictive ability is better. © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley Sons Australia, Ltd.INTR
Like
Comment
Share
